Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Surmodics Expects FY24 Sales Of $117M-$121M, And $113M-$117M, Excluding SurVeil DCB License Fee Revenue, Compared To The Prior Guidance Of $116M-$121M, And $112M-$117M, Respectively, And The Consensus Of $119.26M

Author: Benzinga Newsdesk | February 01, 2024 08:13am

Posted In: SRDX